Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:DGX NASDAQ:EXAS NASDAQ:MYGN NASDAQ:NTRA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDGXQuest Diagnostics$206.34-0.5%$199.13$164.65▼$219.20$22.84B0.58935,552 shs186,481 shsEXASExact Sciences$104.91$103.67$38.81▼$104.98$20.03B1.413.55 million shsN/AMYGNMyriad Genetics$5.84-0.4%$4.65$3.53▼$8.59$553.95M1.641.61 million shs99,085 shsNTRANatera$275.64+1.0%$228.87$131.81▼$288.04$39.36B1.511.38 million shs144,815 shs7 Stocks That Could Lead the Next Market BoomTesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDGXQuest Diagnostics-0.15%-2.89%+2.30%+6.84%+23.39%EXASExact Sciences0.00%0.00%0.00%0.00%+102.10%MYGNMyriad Genetics+0.51%-2.82%+35.33%+19.35%+9.74%NTRANatera+1.09%-3.84%+28.68%+27.14%+70.10%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDGXQuest Diagnostics$206.34-0.5%$199.13$164.65▼$219.20$22.84B0.58935,552 shs186,481 shsEXASExact Sciences$104.91$103.67$38.81▼$104.98$20.03B1.413.55 million shsN/AMYGNMyriad Genetics$5.84-0.4%$4.65$3.53▼$8.59$553.95M1.641.61 million shs99,085 shsNTRANatera$275.64+1.0%$228.87$131.81▼$288.04$39.36B1.511.38 million shs144,815 shs7 Stocks That Could Lead the Next Market BoomTesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDGXQuest Diagnostics-0.15%-2.89%+2.30%+6.84%+23.39%EXASExact Sciences0.00%0.00%0.00%0.00%+102.10%MYGNMyriad Genetics+0.51%-2.82%+35.33%+19.35%+9.74%NTRANatera+1.09%-3.84%+28.68%+27.14%+70.10%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDGXQuest Diagnostics 2.50Moderate Buy$217.175.25% UpsideEXASExact Sciences 1.95Reduce$92.13-12.19% DownsideMYGNMyriad Genetics 2.00Hold$6.5011.34% UpsideNTRANatera 2.86Moderate Buy$267.83-2.83% DownsideCurrent Analyst Ratings BreakdownLatest MYGN, DGX, EXAS, and NTRA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/14/2026NTRANatera Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$285.00 ➝ $330.007/13/2026DGXQuest Diagnostics Robert W. BairdSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$232.00 ➝ $236.007/9/2026DGXQuest Diagnostics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeBuy (B) ➝ Buy (B+)7/9/2026NTRANatera Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$250.00 ➝ $310.007/6/2026NTRANatera EvercoreSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$300.006/29/2026NTRANatera GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$270.00 ➝ $290.006/26/2026NTRANatera Sanford C. BernsteinSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$310.006/25/2026NTRANatera Sanford C. BernsteinSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy6/24/2026DGXQuest Diagnostics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy (B+) ➝ Buy (B)6/24/2026MYGNMyriad Genetics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)6/24/2026NTRANatera BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetBuy$250.00 ➝ $275.00(Data available from 7/14/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDGXQuest Diagnostics$11.04B2.07$15.09 per share13.67$64.78 per share3.19EXASExact Sciences$3.25B6.17$1.27 per share82.83$12.58 per share8.34MYGNMyriad Genetics$824.50M0.67$3.77 per share1.55$3.95 per share1.48NTRANatera$2.31B17.12N/AN/A$12.38 per share22.27Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDGXQuest Diagnostics$992M$9.0522.8017.852.479.07%15.60%7.06%7/23/2026 (Estimated)EXASExact Sciences-$207.95M-$1.10N/A209.822.02-6.40%0.53%0.22%N/AMYGNMyriad Genetics-$365.90M-$4.30N/AN/AN/A-48.24%-8.51%-4.48%8/4/2026 (Estimated)NTRANatera-$208.16M-$1.63N/AN/AN/A-9.05%-14.74%-10.27%8/6/2026 (Estimated)Latest MYGN, DGX, EXAS, and NTRA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/6/2026Q2 2026NTRANatera-$0.4894N/AN/AN/A$662.14 millionN/A8/4/2026Q2 2026MYGNMyriad Genetics-$0.03N/AN/AN/A$206.03 millionN/A7/23/2026Q2 2026DGXQuest Diagnostics$2.81N/AN/AN/A$2.97 billionN/A5/5/2026Q1 2026MYGNMyriad Genetics-$0.06-$0.09-$0.03-$0.36$202.42 million$200.40 million4/21/2026Q1 2026DGXQuest Diagnostics$2.37$2.50+$0.13$2.24$2.83 billion$2.90 billionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthDGXQuest Diagnostics$3.441.67%+7.34%38.01%14 YearsEXASExact SciencesN/AN/AN/AN/AN/AMYGNMyriad GeneticsN/AN/AN/AN/AN/ANTRANateraN/AN/AN/AN/AN/ALatest MYGN, DGX, EXAS, and NTRA DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date5/19/2026DGXQuest Diagnosticsquarterly$0.861.65%7/8/20267/8/20267/22/2026(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDGXQuest Diagnostics0.671.181.08EXASExact Sciences0.972.432.17MYGNMyriad Genetics0.362.402.19NTRANateraN/A2.962.83Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDGXQuest Diagnostics88.06%EXASExact Sciences88.82%MYGNMyriad Genetics99.02%NTRANatera99.90%Insider OwnershipCompanyInsider OwnershipDGXQuest Diagnostics0.88%EXASExact Sciences1.20%MYGNMyriad Genetics1.90%NTRANatera5.05%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableDGXQuest Diagnostics57,000110.70 million109.72 millionOptionableEXASExact Sciences7,200190.89 million188.60 millionOptionableMYGNMyriad Genetics2,70094.45 million92.65 millionOptionableNTRANatera6,140143.21 million135.98 millionOptionableMYGN, DGX, EXAS, and NTRA HeadlinesRecent News About These CompaniesNatera (NASDAQ:NTRA) Given New $330.00 Price Target at Canaccord Genuity Group3 hours ago | marketbeat.comNatera, Inc. $NTRA Shares Sold by Kornitzer Capital Management Inc. KSJuly 12 at 12:47 PM | marketbeat.comCandriam S.C.A. Decreases Stock Holdings in Natera, Inc. $NTRAJuly 12 at 10:41 AM | marketbeat.comDid EU Class C Status for Signatera Reshape Natera’s (NTRA) Long-Term Diagnostics Strategy?July 11 at 2:27 PM | finance.yahoo.comNatera (NTRA) Secures EU Certification, Is The Upside Already Priced In?July 10, 2026 | finance.yahoo.comNatera (NTRA) Stock Still Looks Expensive After A Very Large RunJuly 10, 2026 | finance.yahoo.comNatera (NTRA) Signatera Data Shows Who Benefits From Chemotherapy After CRC SurgeryJuly 10, 2026 | finance.yahoo.comNTRA's Signatera Gains EU IVDR Certification for Multiple CancersJuly 10, 2026 | zacks.comNatera, Inc. $NTRA Shares Sold by Sumitomo Mitsui Trust Group Inc.July 10, 2026 | marketbeat.comWhy Investors Need to Take Advantage of These 2 Medical Stocks NowJuly 9, 2026 | zacks.comNatera Announces IVDR Certification for Signatera™ Across Multiple CancersJuly 9, 2026 | businesswire.comNatera (NASDAQ:NTRA) Insider Sells $818,700.00 in StockJuly 7, 2026 | insidertrades.comNatera (NASDAQ:NTRA) Insider Solomon Moshkevich Sells 3,000 Shares of StockJuly 7, 2026 | americanbankingnews.comSignatera™ MRD Test Predicted Overall Survival Benefit from Chemotherapy in Resected Metastatic Colorectal CancerJuly 6, 2026 | businesswire.comNatera’s Earnings Call Signals Strong Growth MomentumJuly 6, 2026 | theglobeandmail.comY Intercept Hong Kong Ltd Purchases Shares of 28,023 Natera, Inc. $NTRAJuly 5, 2026 | marketbeat.comK.J. Harrison & Partners Inc Sells 4,000 Shares of Natera, Inc. $NTRAJuly 5, 2026 | marketbeat.comNTRA & Aveta Partner to Advance MRD-Guided Trial in Head & Neck CancerJuly 1, 2026 | zacks.comMedical services name tests for colon cancer. Natera stock hits a highJune 30, 2026 | msn.comNatera, Aveta partner on late-stage head and neck cancer trialJune 29, 2026 | reuters.comNatera and Aveta Biomics Announce Strategic Partnership Supporting Global Phase 3 Registrational Trial of APG-157 in Head and Neck CancerJune 29, 2026 | businesswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesMission Control: Floating In SpaceX's Record-Breaking OrbitBy Jeffrey Neal Johnson | June 15, 2026Gravity Check: Houston, SpaceX Has a Valuation ProblemBy Jeffrey Neal Johnson | June 16, 20265 Tech Stocks to Buy on the July PullbackBy Thomas Hughes | June 29, 2026The Oil Trade May Not Be Over: 3 Energy Stocks to WatchBy Thomas Hughes | June 21, 2026These AI Stocks Have Insider Selling, But Buyers Still Have a Reason to StayBy Thomas Hughes | June 23, 2026MYGN, DGX, EXAS, and NTRA Company DescriptionsQuest Diagnostics NYSE:DGX$206.34 -1.01 (-0.49%) As of 11:15 AM Eastern This is a fair market value price provided by Massive. Learn more.Quest Diagnostics Incorporated provides diagnostic testing and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to physicians, hospitals, patients and consumers, health plans, government agencies, employers, retailers, pharmaceutical companies and insurers, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile phlebotomists, nurses, and other health and wellness professionals. The company also provides risk assessment services for the life insurance industry; and healthcare organizations and clinicians information technology solutions. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.Exact Sciences NASDAQ:EXASExact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research, and Johns Hopkins University. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.Myriad Genetics NASDAQ:MYGN$5.84 -0.02 (-0.38%) As of 11:16 AM Eastern This is a fair market value price provided by Massive. Learn more.Myriad Genetics, Inc., a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. The company also offers Prolaris Prostate Cancer Prognostic Test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. It provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek, a non-invasive blood test that predicts the gender of a fetus; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for patients suffering from depression, anxiety, attention-deficit, hyperactivity disorder, and other mental health conditions. It has a strategic collaboration with Illumina, Inc., Memorial Sloan Kettering Cancer Center, the University of Texas MD Anderson Cancer Center, SimonMed, and Onsite Women's Health. Myriad Genetics, Inc. was incorporated in 1992 and is headquartered in Salt Lake City, Utah.Natera NASDAQ:NTRA$275.64 +2.75 (+1.01%) As of 11:16 AM Eastern This is a fair market value price provided by Massive. Learn more.Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born. The company also provides Signatera, a ctDNA blood test for molecular residual disease assessment and surveillance of disease recurrence in patients previously diagnosed with cancer; Altera, a tissue based comprehensive genomic profiling test; Prospera to assess active rejection in patients who have undergone kidney, heart, and lung transplantation; and Renasight, a kidney gene panel test. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics to validate and launch tests. The company offers products through its direct sales force, as well as through a network of laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was founded in 2003 and is headquartered in Austin, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Baggage Claim: Apollo’s $7.7 Billion Bid to Acquire easyJet The SK Hynix IPO and 2027’s AI Memory Squeeze Why Welltower's Growth Story Might Outrun Its Rich Valuation Why Micron Is Doubling Down While the HBM Shortage Persists AMD's 5C Deal Positions It as a Direct NVIDIA Rival China's Helium Ban Could Reshape the AI Supply Chain Fission for Profits: Unlocking America’s Uranium Vault The Phase 3 Failure That Sent Biotech Winners and Losers in Opposite Directions Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
